WEBVTT

1
00:00:02.000 --> 00:00:08.200
Eloralintide is a once-weekly amylin analog developed by Eli Lilly.

2
00:00:09.060 --> 00:00:11.280
Its design asks a focused question.

3
00:00:11.820 --> 00:00:15.660
Can receptor selectivity improve the treatment of obesity?

4
00:00:16.540 --> 00:00:21.000
Daniel Briere and colleagues described its discovery in 2025.

5
00:00:22.040 --> 00:00:25.500
Human receptor assays found 12 times greater potency

6
00:00:25.500 --> 00:00:29.460
at the amylin-one receptor than at the calcitonin receptor.

7
00:00:30.280 --> 00:00:31.660
That is a laboratory measurement.

8
00:00:31.660 --> 00:00:34.160
It does not mean 12 times more weight

9
00:00:34.160 --> 00:00:37.220
loss or prove better tolerability in patients.

10
00:00:38.000 --> 00:00:42.640
Liana Billings and colleagues studied 263 adults for

11
00:00:42.640 --> 00:00:46.480
48 weeks in a randomized phase 2 trial.

12
00:00:47.200 --> 00:00:50.360
Participants had obesity or overweight with a related

13
00:00:50.360 --> 00:00:53.180
condition without type 2 diabetes.

14
00:00:54.120 --> 00:00:58.260
Estimated average weight reductions ranged from 9.5 to

15
00:00:58.260 --> 00:01:05.260
20.1% across six active groups versus 0.4% with placebo.

16
00:01:06.140 --> 00:01:09.480
These estimates assume participants remained on treatment.

17
00:01:09.950 --> 00:01:14.873
Weight loss is only part of the picture. Tolerability matters too.

18
00:01:15.343 --> 00:01:18.163
Gastrointestinal symptoms and fatigue were common.

19
00:01:18.743 --> 00:01:22.463
Slower dose escalation was associated with fewer of these events.

20
00:01:23.183 --> 00:01:27.123
Long-term safety and sustained benefit remain research questions.

21
00:01:27.903 --> 00:01:29.183
As of October 14,

22
00:01:29.963 --> 00:01:36.223
2026, Eloralintide remains investigational with phase 3 studies underway.

23
00:01:36.223 --> 00:01:40.523
Tirzepatide combination results are separate evidence.

24
00:01:41.263 --> 00:01:43.183
Next, survodutide.

25
00:01:43.403 --> 00:01:46.375
The next chapter depends on longer-term evidence.

26
00:01:46.595 --> 00:01:48.075
Peptides in 2.

27
00:01:48.075 --> 00:01:49.895
World Peptide Foundation.

28
00:01:50.615 --> 00:01:51.895
Every experience matters.